Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
VYNE Therapeutics Inc. | Chief Commercial Officer | Common Stock | 109K | $249K | $2.28 | Jun 30, 2021 | Direct |
BioXcel Therapeutics, Inc. | Chief Commercial Officer | Restricted Stock Units | 8.25K | $10.4K | $1.26 | Jun 15, 2024 | Direct |
BioXcel Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 3.5K | $4.42K | $1.26 | Jun 17, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BTAI | BioXcel Therapeutics, Inc. | Jun 15, 2024 | 3 | -$308 | 4 | Jun 18, 2024 | Chief Commercial Officer |
BTAI | BioXcel Therapeutics, Inc. | Mar 15, 2024 | 3 | -$2.66K | 4 | Apr 8, 2024 | CHIEF COMMERCIAL OFFICER |
BTAI | BioXcel Therapeutics, Inc. | Mar 15, 2023 | 2 | $0 | 4 | Mar 16, 2023 | CHIEF COMMERCIAL OFFICER |
BTAI | BioXcel Therapeutics, Inc. | Jan 17, 2022 | 1 | $0 | 4 | Jan 19, 2022 | CHIEF COMMERCIAL OFFICER |
BTAI | BioXcel Therapeutics, Inc. | Jan 17, 2022 | 0 | $0 | 3 | Jan 19, 2022 | CHIEF COMMERCIAL OFFICER |
VYNE | VYNE Therapeutics Inc. | Jun 30, 2021 | 1 | -$18.1K | 4 | Jul 2, 2021 | Chief Commercial Officer |